Symptoms of Lymphoma

Lymphoma symptoms vary depending on the subtype, stage, and sites of involvement. The hallmark presentation is painless lymph node enlargement, but symptoms can be diverse due to the widespread distribution of lymphatic tissue:

Lymphadenopathy (Enlarged Lymph Nodes): The most common presenting sign. Lymph nodes are typically firm, rubbery, non-tender, and mobile. They most commonly appear in the cervical (neck), supraclavicular, axillary (armpit), or inguinal (groin) regions. Unlike reactive lymphadenopathy from infection, lymphoma-related lymphadenopathy persists and progressively enlarges.

B Symptoms (Constitutional Symptoms): These are important prognostic indicators in both HL and NHL:

• Unexplained Fever: Temperature >38 degrees Celsius without evidence of infection. Pel-Ebstein fever (cyclical fevers) is classically described in HL but is uncommon.
• Drenching Night Sweats: Profuse sweating that soaks sleepwear and bedding, requiring changing of clothes.
• Unintentional Weight Loss: Loss of more than 10% of body weight over the preceding 6 months.

Other Constitutional Symptoms: Severe fatigue interfering with daily activities, pruritus (itching) without rash (particularly in HL), and anorexia.

Mediastinal Involvement: Anterior mediastinal mass can cause cough, chest pain, dyspnea (shortness of breath), stridor, dysphagia, and superior vena cava syndrome (facial swelling, neck vein distention, arm edema). This is common in nodular sclerosis HL and primary mediastinal B-cell lymphoma.

Abdominal and Pelvic Involvement: Splenomegaly causing left upper quadrant fullness and early satiety; hepatomegaly; abdominal pain or distention; ascites; bowel obstruction; and ureteral obstruction.

Extranodal Symptoms (More Common in NHL):

• Gastrointestinal: Abdominal pain, nausea, vomiting, GI bleeding, or obstruction from gastric or intestinal lymphoma.
• Skin: Erythematous to violaceous nodules, plaques, or tumors in cutaneous T-cell or B-cell lymphomas.
• Central Nervous System: Headache, confusion, seizures, cranial nerve palsies, or focal neurological deficits in primary or secondary CNS lymphoma.
• Bone: Bone pain, pathological fractures, or spinal cord compression.
• Bone Marrow: Cytopenias (anemia, thrombocytopenia, neutropenia) due to marrow infiltration causing fatigue, bleeding, and infections.

Alcohol-Induced Pain: Pain in involved lymph nodes within minutes of alcohol consumption, a rare but classic symptom of Hodgkin lymphoma.

Treatment Approaches for Lymphoma

Treatment for lymphoma depends on the type (Hodgkin vs. non-Hodgkin), histological subtype, stage, prognostic factors, and the patient's age and overall health. At Guangzhou Fosun Chancheng Hospital, our multidisciplinary team develops individualized treatment strategies:

Chemotherapy: The backbone of lymphoma treatment across most subtypes:

• Hodgkin Lymphoma: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is the standard first-line regimen. Escalated BEACOPP may be used for advanced-stage high-risk disease. Brentuximab vedotin + AVD is an option for advanced-stage disease.
• Diffuse Large B-Cell Lymphoma (DLBCL): R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the standard of care. Dose-adjusted EPOCH-R may be used for high-risk subtypes.
• Follicular Lymphoma: Bendamustine + rituximab (BR) or R-CHOP for symptomatic or high-tumor-burden disease. Rituximab monotherapy for low-burden disease.
• Mantle Cell Lymphoma: Intensive induction with cytarabine-containing regimens followed by autologous stem cell transplantation in younger patients; BTK inhibitors (ibrutinib, acalabrutinib) in relapsed settings.
• Burkitt Lymphoma: Intensive short-course regimens (CODOX-M/IVAC, Hyper-CVAD) with CNS prophylaxis due to high risk of CNS relapse.

Immunotherapy and Targeted Therapy:

• Monoclonal Antibodies: Rituximab (anti-CD20) revolutionized B-cell NHL treatment and is incorporated into most B-cell lymphoma regimens. Obinutuzumab is a glycoengineered anti-CD20 antibody used in follicular lymphoma.
• Antibody-Drug Conjugates (ADCs): Brentuximab vedotin (anti-CD30) in HL and anaplastic large cell lymphoma. Polatuzumab vedotin (anti-CD79b) in DLBCL. Loncastuximab tesirine (anti-CD19) in relapsed DLBCL.
• Bispecific Antibodies: Mosunetuzumab (CD20/CD3) and epcoritamab (CD20/CD3) engage T cells to kill B-cell lymphoma cells.
• Immune Checkpoint Inhibitors: Pembrolizumab and nivolumab are effective in relapsed/refractory classical HL.

CAR T-Cell Therapy: Axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, and brexucabtagene autoleucel are approved CD19-directed CAR T-cell therapies for relapsed/refractory aggressive B-cell lymphomas. These can produce durable remissions in patients with chemotherapy-refractory disease.

Radiation Therapy: Involved-site radiation therapy (ISRT) is used for early-stage HL and limited-stage aggressive NHL as consolidation after abbreviated chemotherapy. Radiation is also effective for palliation of symptomatic disease sites.

Stem Cell Transplantation: High-dose chemotherapy with autologous stem cell rescue is the standard second-line treatment for relapsed chemosensitive DLBCL and HL. Allogeneic HSCT may be considered for younger patients with relapsed/refractory disease.

Watchful Waiting (Active Surveillance): For asymptomatic low-tumor-burden indolent lymphomas (follicular lymphoma, small lymphocytic lymphoma), observation without immediate treatment is a standard option.

Prognosis of Lymphoma

The prognosis of lymphoma varies widely depending on the specific subtype, stage, prognostic indices, and response to therapy. Significant therapeutic advances in immunotherapy and targeted agents have dramatically improved outcomes for many subtypes:

Hodgkin Lymphoma (HL):

• Overall Prognosis: One of the most curable malignancies. 5-year overall survival exceeds 85% for all stages combined. Early-stage favorable HL has cure rates exceeding 95% with combined modality therapy.
• Advanced-Stage HL: 5-year progression-free survival of 70-85% with ABVD or escalated BEACOPP. Interim PET-CT after 2 cycles (PET2) is the strongest predictor of outcome and guides treatment adaptation.
• Relapsed/Refractory HL: High-dose chemotherapy with autologous stem cell transplantation achieves cure in 40-50% of chemosensitive patients. Checkpoint inhibitors (nivolumab, pembrolizumab) and brentuximab vedotin have further improved salvage outcomes.

Diffuse Large B-Cell Lymphoma (DLBCL):

• International Prognostic Index (IPI): Risk-stratifies patients based on age >60, elevated LDH, ECOG performance status >1, stage III/IV, and >1 extranodal site. Low-risk (0-1 factors): 5-year survival >90%; high-intermediate risk (3 factors): 5-year survival ~50%; high-risk (4-5 factors): 5-year survival ~30%.
• Cell of Origin: Germinal center B-cell (GCB) subtype has better prognosis than activated B-cell (ABC) subtype with R-CHOP. Novel agents targeting B-cell receptor and NF-kB pathways are improving outcomes in ABC-DLBCL.
• Relapsed/Refractory DLBCL: CAR T-cell therapy has produced durable remissions in 30-40% of patients who would otherwise have a median survival of <6 months.

Follicular Lymphoma: Indolent but generally incurable with conventional therapy. Median overall survival exceeds 18-20 years in the rituximab era. FLIPI (Follicular Lymphoma International Prognostic Index) risk score predicts outcome. Transformation to aggressive lymphoma (3% per year) worsens prognosis significantly.

Mantle Cell Lymphoma: Median overall survival 5-10 years with modern therapy. Cytarabine-containing induction followed by autologous HSCT consolidation in younger patients and rituximab maintenance have improved outcomes. BTK inhibitors are highly active in relapsed disease.

Burkitt Lymphoma: Highly aggressive but curable with intensive chemotherapy. Cure rates exceed 80-90% in children and 60-80% in adults with modern protocols. CNS involvement at diagnosis worsens prognosis.

Precautions and Lifestyle Recommendations for Lymphoma Patients

Patients undergoing treatment for lymphoma require comprehensive management of treatment-related toxicities and vigilant surveillance for recurrence:

Infection Prevention: Lymphoma and its treatment cause significant immunosuppression. Patients must practice rigorous hand hygiene, avoid individuals with active respiratory or other infections, avoid crowded indoor spaces during neutropenic periods, and report any fever above 38 degrees Celsius immediately. Prophylactic antibiotics, antivirals, and Pneumocystis jirovecii pneumonia (PJP) prophylaxis with trimethoprim-sulfamethoxazole are standard during certain regimens.

Chemotherapy-Related Toxicity Monitoring:

• Cardiotoxicity: Anthracyclines (doxorubicin) used in CHOP and ABVD can cause cumulative dose-dependent cardiac dysfunction. Baseline echocardiogram and periodic monitoring of cardiac function are essential. Report new-onset dyspnea, orthopnea, or pedal edema promptly.
• Pulmonary Toxicity: Bleomycin in ABVD can cause pneumonitis and pulmonary fibrosis. High-concentration supplemental oxygen during surgery and scuba diving should be avoided lifelong in patients who have received bleomycin.
• Neurotoxicity: Vincristine and brentuximab vedotin can cause peripheral neuropathy (numbness, tingling, pain in hands and feet). Report symptoms early to allow dose modification.
• Tumor Lysis Syndrome: High-risk patients (Burkitt lymphoma, high-burden disease) require aggressive hydration, allopurinol or rasburicase prophylaxis, and close electrolyte monitoring during initial therapy.

Vaccination and Immunization: Live vaccines are contraindicated during active treatment. Inactivated influenza and COVID-19 vaccines can be administered but may have reduced efficacy. Post-treatment revaccination schedule should follow ASCO/IDSA guidelines, typically beginning 3-6 months after completion of chemotherapy and 6-24 months after HSCT.

Long-Term Survivorship Surveillance:

• Secondary Malignancies: Increased risk of therapy-related MDS/AML (particularly with alkylating agents and topoisomerase II inhibitors), solid tumors (lung, breast, thyroid), and non-melanoma skin cancers. Lifelong adherence to age-appropriate cancer screening is critical.
• Cardiovascular Disease: Mediastinal radiation and anthracycline exposure increase risk of coronary artery disease, valvular heart disease, and cardiomyopathy. Regular cardiovascular risk assessment is recommended.
• Hypothyroidism: Neck or mediastinal radiation can cause hypothyroidism requiring lifelong thyroid hormone replacement and periodic TSH monitoring.

Nutrition and Lifestyle: Maintain a balanced diet rich in fruits, vegetables, and whole grains; limit processed meats and alcohol. During neutropenia, follow food safety guidelines (avoid unpasteurized dairy, raw or undercooked foods). Regular moderate exercise helps combat fatigue and maintains muscle mass.

Psychological Support: The lymphoma journey can be psychologically demanding. Seek counseling, join support groups (Leukemia & Lymphoma Society), and address anxiety, depression, and fear of recurrence proactively.